Close Menu

This article has been updated from a previous version to include comments made by Fluidigm's CEO in an earnings call.

NEW YORK – Fluidigm reported after the close of the market on Thursday that its second quarter revenues decreased 8 percent year over year.

For the three months ended June 30, 2020, Fluidigm tallied $26.1 million in revenues compared to $28.2 million a year ago, but ahead of analysts' consensus estimate of $19.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.